Document is current

Article History

Accepted: 16 October 2024

First Online: 13 November 2024

Competing interests

: J.M.G. has served as a consultant for and has received honoraria from Abbvie, Artax (Data Safety and Monitoring Board (DSMB)), BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies), GSK, Inmagene (DSMB), Lilly, Leo, Moonlake (DSMB), Janssen Biologics, Neuroderm (DSMB), Novartis, UCB (DSMB) and Veolia North America; receives research grants (to the trustees of the University of Pennsylvania) from Amgen, BMS and Pfizer; received payment for continuing medical education work related to psoriasis that was supported indirectly by pharmaceutical sponsors; is a co-patent holder of resiquimod for the treatment of cutaneous T cell lymphoma; is a Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology; is Chief Medical Editor for Healio Dermatology (receiving honoraria); and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society (receiving no honoraria). M.S.G. has received consultant fees from Agepha, BMS, Horizon Therapeutics and Kiniksa, has received research grant support from Pfizer, and is supported by an NIH NHLBI grant (K23HL152013). The other authors declare no competing interests.